GLP-1 receptor agonists, dual and triple agonists, and metabolic regulation studies.
Incretin mechanism and GLP-1 receptor agonist clinical landscape.
Read ArticleSUSTAIN, STEP, and SELECT programs and cardiovascular outcomes.
Read ArticleSURPASS and SURMOUNT programs demonstrating up to 22.5% weight reduction.
Read ArticlePhase 2 findings on triple receptor agonism and metabolic outcomes.
Read Article